As of June 18, 2025, Calliditas Therapeutics AB (CALTX.ST) reports a Current Ratio of 3.13.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Calliditas Therapeutics AB's Current Ratio
Over recent years, Calliditas Therapeutics AB's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2023-12-31 | 3.13 |
| 2022-12-31 | 4.34 |
| 2021-12-31 | 7.48 |
| 2020-12-31 | 9.82 |
| 2019-12-31 | 15.39 |
This gradual decrease highlights how Calliditas Therapeutics AB manages its short-term assets and liabilities over time.
Comparing Calliditas Therapeutics AB's Current Ratio to Peers
To better understand Calliditas Therapeutics AB's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Calliditas Therapeutics AB (CALTX.ST) | 3.13 |
| InDex Pharmaceuticals Holding AB (INDEX.ST) | 23.57 |
| Oncoarendi Therapeutics SA (OAT.WA) | 19.67 |
| Moberg Pharma AB (publ) (MOB.ST) | 17.95 |
| Camurus AB (CAMX.ST) | 8.09 |
| Enzymatica AB (publ) (ENZY.ST) | 6.82 |
Compared to its competitors, Calliditas Therapeutics AB's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.